Back to Journals » Patient Preference and Adherence » Volume 2

Patient perspectives in the management of overactive bladder, focus on transdermal oxybutynin

Authors Tondalaya Gamble, Peter Sand

Published 17 November 2008 Volume 2008:2 Pages 349—356

DOI https://doi.org/10.2147/PPA.S3417

Review by Single-blind

Peer reviewer comments 3

Tondalaya Gamble, Peter Sand

Evanston Continence Center, Division of Urogynecology, Department of Obstetrics and Gynecology, Evanston Northwestern Healthcare, Northwestern University, Feinberg School of Medicine, Evanston, Illinois

Abstract: Overactive bladder syndrome (OAB) is a constellation of distressing symptoms that significantly impair quality of life, sexual function, and work productivity, and imposes a significant economic burden to society. Pharmacological treatment with antimuscarinic agents, behavioral modification, bladder retraining, and/or pelvic floor exercises are often used alone or in combination as the mainstay treatment in the management of OAB. Oxybutynin has been used in the treatment of OAB for over 20 years with proven efficacy and is often the comparator in drug treatment trials. Oral formulations of oxybutynin have proven efficacy, but not without significant antimuscarinic effects, which reduce patient persistence with medical treatment. Low levels of patient persistence with oral formulations of oxybutynin provided an impetus for the development of a transdermal oxybutynin delivery system. The oxybutynin transdermal formulation has been found to have side effects similar to that of a placebo in randomized controlled trials while providing excellent efficacy. Patient persistence with therapy, improved quality of life, sexual function and interpersonal relationships have been observed with use of the transdermal oxybutynin delivery system. Its twice weekly dosing, low side effect profile, and high efficacy have made it a good choice for initial treatment of overactive bladder syndrome.

Keywords: overactive bladder syndrome, oxybutynin, transdermal delivery

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

In vitro study of novel gadolinium-loaded liposomes guided by GBI-10 aptamer for promising tumor targeting and tumor diagnosis by magnetic resonance imaging

Gu MJ, Li KF, Zhang LX, Wang H, Liu LS, Zheng ZZ, Han NY, Yang ZJ, Fan TY

International Journal of Nanomedicine 2015, 10:5187-5204

Published Date: 17 August 2015

External beam radiotherapy synergizes 188Re-liposome against human esophageal cancer xenograft and modulates 188Re-liposome pharmacokinetics

Chang CH, Liu SY, Chi CW, Yu HL, Chang TJ, Tsai TH, Lee TW, Chen YJ

International Journal of Nanomedicine 2015, 10:3641-3649

Published Date: 19 May 2015

Interaction between nanoparticles generated by zinc chloride treatment and oxidative responses in rat liver

Azzouz I, Trabelsi H, Hanini A, Ferchichi S, Tebourbi O, Sakly M, Abdelmelek H

International Journal of Nanomedicine 2014, 9:223-229

Published Date: 27 December 2013

Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy

Gold M, Lorenzl S, Stewart AJ, Morimoto BH, Williams DR, Gozes I

Neuropsychiatric Disease and Treatment 2012, 8:85-93

Published Date: 9 February 2012

ISVH – October Newsletter

Prof. Roland Asmar, David Oldfield

Vascular Health and Risk Management 2008, 4:1145-1146

Published Date: 10 October 2008

Health professionals’ experiences of person-centered collaboration in mental health care

Rita Sommerseth, Elin Dysvik

Patient Preference and Adherence 2008, 2:259-269

Published Date: 9 October 2008

Patient’s compliance with allergen immunotherapy

Cristoforo Incorvaia, Marina Mauro, Erminia Ridolo, Paola Puccinelli, Massimiliano Liuzzo, et al

Patient Preference and Adherence 2008, 2:247-251

Published Date: 15 September 2008

Erratum

Erhardt L, Moller R, Puig JC. 2007

Vascular Health and Risk Management 2008, 4:741-741

Published Date: 6 June 2008

Predictors of adherence among community users of a cognitive behavior therapy website

Philip J Batterham, Alison L Neil, Kylie Bennett, Kathleen M Griffiths, Helen Christensen

Patient Preference and Adherence 2008, 2:97-105

Published Date: 19 March 2008